An integrated radiology-pathology machine learning classifier for outcome prediction following radical prostatectomy: Preliminary findings.

To evaluate the added benefit of integrating features from pre-treatment MRI (radiomics) and digitized post-surgical pathology slides (pathomics) in prostate cancer (PCa) patients for prognosticating outcomes post radical-prostatectomy (RP) including a) rising prostate specific antigen (PSA), and b) extraprostatic-extension (EPE). Multi-institutional data (N = 58) of PCa patients who underwent pre-treatment 3-T MRI prior to RP were included in this retrospective study. Radiomic and pathomic features were extracted from PCa regions on MRI and RP specimens delineated by expert clinicians. On training set (D1, N = 44), Cox Proportional-Hazards models M Patients had median follow-up of 34 months. M Results from this preliminary study suggest that a combination of radiomic and pathomic features can better predict post-surgical outcomes (rising PSA and EPE) compared to either of them individually as well as extant prognostic nomogram (CAPRA).

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

Dr. Anant Madabhushi is an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol Meyers-Squibb and Merck. Currently he serves on the advisory board of Aiforia Inc. He also has sponsored research agreements with Philips, AstraZeneca and Bristol Meyers-Squibb. His technology has been licensed to Elucid Bioimaging. He is also involved in a NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc (NIH 1R01CA202752-01A1: Computerized histologic image predictor of cancer outcome, NIH 1 R01 CA216579-01A1: Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers, NIH 1 R01 CA220581-01A1: Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal Carcinoma). Dr. Andrei Purysko: service contract with Profound Medical and Research support from RSNA R&E foundation. Dr. Patrick Leo is employed in Genentech and have Roche group stock.